albumin baxalta 50 g/ l
baxalta innovations gmbh - albumin, humant - infusjonsvæske, oppløsning - 50 g/ l
covexin 8 vet
zoetis animal health aps - clostridium perfringens, type a, alfa toksoid / clostridium perfringens, type b/ c, beta toksoid / clostridium perfringens, type d, epsilon toksoid / clostridium chauvoei, inaktivert / clostridium novyi, inaktivert / clostridium septikum, inaktivert / clostridium tetani, inaktivert / clostridium sordellii, toksoid / clostridium haemolyticum, inaktivert - injeksjonsvæske, suspensjon
gelaspan
b. braun melsungen ag - gelatin, suksinylert / natriumklorid / natriumacetattrihydrat / kaliumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat - infusjonsvæske, oppløsning
sporimune vet 50 mg/ ml
le vet beheer b.v. - ciklosporin - mikstur, oppløsning - 50 mg/ ml
sterile water fresenius kabi -
fresenius kabi norge as - halden - vann til injeksjonsvæsker - oppløsningsvæske til parenteral bruk
tribovax vet
intervet international bv - 5831 an - clostridium perfringens, type a, alfa toksoid / clostridium perfringens, type b/ c, beta toksoid / clostridium perfringens, type d, epsilon toksoid / clostridium chauvoei, inaktivert / clostridium novyi, inaktivert / clostridium septikum, inaktivert / clostridium tetani, inaktivert / clostridium sordellii, toksoid / clostridium haemolyticum, inaktivert - injeksjonsvæske, suspensjon
uromitexan 400 mg
baxter medical ab - mesna - tablett, filmdrasjert - 400 mg
uromitexan 100 mg/ ml
baxter medical ab - mesna - injeksjonsvæske, oppløsning - 100 mg/ ml
uromitexan 600 mg
baxter medical ab - mesna - tablett, filmdrasjert - 600 mg
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastiske midler - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).